ACE-031
ResearchA myostatin inhibitor targeting the activin type IIB receptor. Researched for muscle wasting diseases and potential muscle growth applications.
Muscle GrowthBody Composition
Half Life
~14 days
Time to Results
4-8 weeks
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyBi-weekly
Cost$$$
🐾 Griffin Says...
ACE-031 trials in Duchenne Muscular Dystrophy were paused due to vascular side effects, which are important to note. The muscle-building mechanism is real but the safety profile needs more research. Not a casual compound.
Benefits
- Myostatin and GDF-11 inhibition
- Muscle mass preservation
- Potential muscle growth
- Muscle wasting disease research
Best For
- Advanced muscle research
- Muscle wasting research
- Sarcopenia research
Body Systems
Musculoskeletal
Mechanisms of Action
- Acts as decoy receptor for myostatin and activin
- Removes muscle growth inhibitors
- Long-acting via Fc fusion protein design
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Nosebleeds (clinical trial finding) | Common in trials | Mild-Moderate |
| Telangiectasias | Common in trials | Moderate |
| Gum bleeding | Common in trials | Mild |
Contraindications
Vascular complications noted in trials, bleeding disorders
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator